Evershine Drug Product Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 18-06-2024
- Paid Up Capital ₹ 1.50 M
as on 18-06-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.94 Cr
as on 18-06-2024
- Satisfied Charges ₹ 7.20 M
as on 18-06-2024
- Revenue -4.48%
(FY 2023)
- Profit 14.38%
(FY 2023)
- Ebitda 76.59%
(FY 2023)
- Net Worth 36.36%
(FY 2023)
- Total Assets 26.22%
(FY 2023)
About Evershine Drug Product
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹1.94 Cr. The company has closed loans amounting to ₹7.20 M, as per Ministry of Corporate Affairs (MCA) records.
Raj Natekar, Prachi Natekar, and Ramesh Natekar serve as directors at the Company.
- CIN/LLPIN
U24239MH2009PTC196882
- Company No.
196882
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Evershine Drug Product?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Natekar  | Director | 27-Feb-2015 | Current |
| Prachi Natekar | Director | 26-Oct-2012 | Current |
| Ramesh Natekar | Director | 25-Mar-2010 | Current |
Financial Performance of Evershine Drug Product.
Evershine Drug Product Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.48% decrease. The company also saw a substantial improvement in profitability, with a 14.38% increase in profit. The company's net worth Soared by an impressive increase of 36.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evershine Drug Product?
In 2023, Evershine Drug Product had a promoter holding of 96.67% and a public holding of 3.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ambika Pharmaceutical Marketing Private LimitedActive 8 years 10 monthsPrachi Natekar and Ramesh Natekar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Dec 2022 | ₹1.94 Cr | Open |
State Bank Of India Creation Date: 23 Dec 2011 | ₹7.20 M | Satisfied |
How Many Employees Work at Evershine Drug Product?
Unlock and access historical data on people associated with Evershine Drug Product, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evershine Drug Product, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evershine Drug Product's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
